Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- MDNA.TO
- Price
- 0.92
- Stock movement up
- +0.02 (2.22%)
- Company name
- Medicenna Therapeutics Corp
- Exchange
- (TO ,
- Currency
- CAD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 76.74M
- Ent value
- 68.79M
- Price/Sales
- -
- Price/Book
- 7.49
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -3.13%
- 1 year return
- -34.75%
- 3 year return
- -
- 5 year return
- -
- 10 year return
- -
Last updated: 2026-01-22
DIVIDENDS
MDNA.TO does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 7.49 |
| EV to Sales | - |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 83.41M |
| EPS (TTM) | -0.17 |
| FCF per share (TTM) | -0.48 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | -59.00K |
| Operating income (TTM) | -21.82M |
| Net income (TTM) | -13.81M |
| EPS (TTM) | -0.17 |
| EPS (1y forward) | -0.37 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 15.75M |
| Net receivables | 1.26M |
| Total current assets | 17.87M |
| Goodwill | 0.00 |
| Intangible assets | 49.00K |
| Property, plant and equipment | 120.00K |
| Total assets | 18.04M |
| Accounts payable | 3.65M |
| Short/Current long term debt | 149.00K |
| Total current liabilities | 4.46M |
| Total liabilities | 7.80M |
| Shareholder's equity | 10.24M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -20.58M |
| Capital expenditures (TTM) | 66.00K |
| Free cash flow (TTM) | -40.08M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -134.89% |
| Return on Assets | -76.58% |
| Return on Invested Capital | -134.89% |
| Cash Return on Invested Capital | -391.36% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.93 |
| Daily high | 0.93 |
| Daily low | 0.89 |
| Daily Volume | 146K |
| All-time high | 7.00 |
| 1y analyst estimate | 3.88 |
| Beta | 1.87 |
| EPS (TTM) | -0.17 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 12 Feb 2026 |
Downside potential
Loading...
Downside potential data
| MDNA.TO | S&P500 | |
| Current price drop from All-time high | -86.86% | -1.40% |
| Highest price drop | -88.57% | -19.00% |
| Date of highest drop | 21 Jul 2025 | 8 Apr 2025 |
| Avg drop from high | -82.18% | -2.49% |
| Avg time to new high | - | 6 days |
| Max time to new high | 322 days | 89 days |
COMPANY DETAILS
Marketcap
76.74M
Marketcap category
Small-cap
Description
Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for the treatment of recurrent glioblastoma. The company also develops MDNA11, a long-acting interleukin-2 (IL-2) to activate anti-cancer immune cells over immunosuppressive Tregs; MDNA209, an IL-2/IL-15 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host diseases; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; MDNA113, a tumor-targeting and activatable masked anti-PD-1-IL-2 BiSKITTM for cancer; and MDNA132, an IL-13 Superkine for various tumors. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.
Employees
18
Website
Investor relations
-
SEC filings
CEO
Country
Canada
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Among monotherapy expansion cohorts (n=21), ORR was 50% in patients treated with MDNA11 in 2L/3L setting and 42% when MDNA11 was the next treatment post-ICI failure, showing best-in-class potential fo...
January 15, 2026
On December 15, 2025, Fahar Merchant, President and Chief Executive Officer of Medicenna Therapeutics Corp. ("Medicenna"), purchased an aggregate of 32,000 common shares of Medicenna (the "Shares") th...
December 15, 2025
MDNA11 demonstrates durable anti-tumor activity in phase-2 eligible expansion cohorts, enriched for immune checkpoint resistant melanoma, MSS endometrial cancer, MSI-H and TMB-H cancers, in each case ...
December 10, 2025
TORONTO and HOUSTON, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the deve...
December 9, 2025
Updated MDNA11 Clinical Data from the ABILITY-1 Study will be Presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress on 10th December, 2025 Fondazion Melanoma Onus will...
November 13, 2025
Medicenna Therapeutics (MDNA.TO) said Thursday its lead candidate MDNA-11 is being tested with two m
November 6, 2025
The Canadian market has shown resilience, closing October near record highs despite potential disruptions from geopolitical tensions and central bank policies. In such a climate, investors often look ...
November 6, 2025
NEO-CYT is a randomized, multi-centre trial of neoadjuvant MDNA11 (before curative intent surgery) sponsored by the Fondazione Melanoma Onlus, and led by Professor Paolo A. Ascierto of the Istituto Na...
November 6, 2025
DelveInsight's Mismatch Repair Deficiency Market Insights report includes a comprehensive understanding of current treatment practices, mismatch repair deficiency emerging drugs, market share of indiv...
October 23, 2025
TORONTO and HOUSTON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the deve...
October 23, 2025
Next page